Work

Intravesical disitamab vedotin (RC48) for patients with HER2-expressing high-risk non-muscle-invasive bladder cancer: A dose-escalation phase I trial.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.4605

Authors: Xu Chen, Ming Huang, Jianmin Fang, Jian Huang, Tianxin Lin

Institutions: Sun Yat-sen Memorial Hospital, Tongji University, Sun Yat-sen University

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410818208

Cites:

Cited by: 1

Related to: 10